目的 探討莫沙必利聯(lián)合奧美拉唑鎂治療反流性食管炎的臨床療效。方法 選取2020年6月-2022年7月在延安大學(xué)附屬醫(yī)院診治的104例反流性食管炎患者，隨機(jī)分為對(duì)照組和治療組，每組各52例。對(duì)照組口服艾司奧美拉唑鎂腸溶片，20 mg/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服枸櫞酸莫沙必利片，2 mg/次，3次/d。兩組患者均連續(xù)治療2個(gè)月。觀察兩組患者臨床療效，比較治療前后兩組患者胃腸激素（GAS）和胃動(dòng)素（MTL）水平及炎性因子白細(xì)胞介素-4（IL-4）、IL-7和IL-17水平，血清血紅素氧合酶-1（HO-1）和瘦素水平。結(jié)果 治療后，治療組總有效率明顯高于對(duì)照組（94.23%vs 76.92%，P<0.05）。治療后，兩組GAS、MTL和IL-4水平明顯升高，而IL-7、IL-17、HO-1和瘦素水平明顯降低（P<0.05），且治療組這些指標(biāo)水平明顯好于對(duì)照組（P<0.05）。結(jié)論 莫沙必利聯(lián)合奧美拉唑鎂治療反流性食管炎具有理想效果，不僅能調(diào)整胃腸激素，并且能降低炎性因子及HO-1、瘦素表達(dá)，且安全性高。

Objective To investigate the effects of mosorapride combined with magnesium omeprazole in treatment of reflux esophagitis. Methods Patients (104 cases) with reflux esophagitis in Yan'an University Affiliated Hospital from June 2020 to Junly 2022 were randomly divided into control and treatment group, and each group had 52 cases. Patients in the control group were po administered with Esomeprazole Magnesium Enteric-coated Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Mosapride Citrate Tablets on the basis of the control group, 2 mg/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluation was evaluated, and the levels of GAS, MTL, IL-4, IL-7, IL-17, HO-1, and leptin in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (94.23% vs 76.92%, P < 0.05). After treatment, the levels of GAS, MTL, and IL-4 were significantly increased, while the levels of IL-7, IL-17, HO-1, and leptin were significantly decreased in two groups (P < 0.05), and the levels of these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Mosapride combined with magnesium omeprazole is effective in treatment of reflux esophagitis. It can not only regulate gastrointestinal hormones, but also reduce the expression of inflammatory factors and HO-1 and leptin.

R975